B7-H3 ADCs: A new contender in small cell lung cancer and beyond

positivePositive

AI Analysis

Summary

Labiotech overview of B7-H3 antibody-drug conjugates as an emerging contender in small cell lung cancer, noting momentum from positive results by Hansoh Pharma and Medilink. The excerpt provides no specific trial data.

Outcome Details

Article states Hansoh Pharma and Medilink have brought momentum to the B7-H3 ADC field with positive results in small cell lung cancer; no specific data provided.

Importance:4/10

Sentiment:

0.50

B7-H3ADCsmall cell lung cancerSCLConcologyindustry overview

Related Companies

$HNPHY

Read the original article

Published by Labiotech.eu on October 19, 2026 1:00 PM

Read Original